Human Papillomavirus Anal Infection

Human PapillomaVirus (HPV) Anal Infection: Study of Prevalence and Risk Factors Among 1000 Patients Benefiting From a Colonoscopy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02862795

Acronym

PAPILLAN

Enrollment

500

Registered

2016-08-11

Start date

2012-04-30

Completion date

2016-06-30

Last updated

2016-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV Infection

Keywords

colonoscopy

Brief summary

Human papillomavirus (HPV) are involved in up to 95 % of anal canal neoplastic lesions. Little is known about HPV carriage in anal canal previous to cancer occurrence in the population and pre-neoplastic lesions, and their risk factors. PAPILLAN is a prospective study that aims to study HPV infection (HPV low grade and high grade genotypes) prevalence in anal canal in a population non selected by its HIV status. In that purpose patients are prospectively recruited in a french university hospital gastroenterology unit and anal smears are collected during a colonoscopy with cytobrush.

Interventions

PROCEDUREHPV detection in anal canal samples

Additional anal taking during the colonoscopy with cytobrush

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients \> 18 years * patients undergoing colonoscopy under general anesthesia for any purpose * signed written consent

Exclusion criteria

* age under 18 * Absence of written consent. * patients incapable of giving consent

Design outcomes

Primary

Measure	Time frame
anal canal HPV infection	at inclusion (the day of colonoscopy)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026